Caplin Point Laboratories is currently trading at Rs. 732.60, up by 5.65 points or 0.78% from its previous closing of Rs. 726.95 on the BSE.
The scrip opened at Rs. 730.00 and has touched a high and low of Rs. 745.00 and Rs. 721.90 respectively. So far 17,104 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 783.90 on 07-Aug-2017 and a 52 week low of Rs. 240.00 on 29-Sep-2016.
Last one week high and low of the scrip stood at Rs. 745.00 and Rs. 685.55 respectively. The current market cap of the company is Rs. 5,536.00 crore.
The promoters holding in the company stood at 69.06%, while Institutions and Non-Institutions held 5.86% and 25.08% respectively.
Caplin Point Laboratories has received approval from the U.S. Food and Drug Administration (USFDA) of its Abbreviated New Drug Application (ANDA) for Ketorolac Tromethamine Injection 30mg/mL, a product developed for Cycle Pharmaceuticals. Ketorolac Tromethamine Injection is a nonsteroidal anti-inflammatory drug (NSAID) and is indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level.
Ketorolac Tromethamine Injection has been developed at Caplin Point and will be manufactured at Caplin’s FDA approved site. Cycle has selected Virtus Pharmaceuticals, LLC (Virtus) as the importer and distributor of Ketorolac Tromethamine Injection in the U.S.
Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.
